

INDEX

A

- Acquired deficiency 356, 366, 374
Activated clotting time (ACT) 155–165
Activated partial thromboplastin time (APTT) 5, 75, 76,
101–104, 106, 107, 111–119, 121, 122, 124,
131–133, 157, 158, 163, 265, 267, 268, 280, 281,
286, 323, 324, 331, 335, 341, 349, 350, 366, 374
Aggregation studies 79
Alert value 69, 189, 422
Angiogenesis 31, 36, 40, 171
Anticardiolipin antibody 98, 387–404
Anticoagulant 7, 9, 37, 38, 49, 52–59,
62, 64–66, 68, 74, 76, 78, 81, 91, 97–107, 111–115,
121–125, 132–134, 151, 156, 159, 164, 165, 193,
194, 198–200, 207, 208, 223, 230, 238, 242, 247,
252, 268, 274, 279, 281, 290, 292, 294, 301, 316,
317, 324, 330, 331, 334, 336, 338, 340, 347,
349–351, 358, 361, 368, 369, 374, 377, 388,
390–394, 397, 398, 400–402
Anti- β 2 glycoprotein I antibody 387–404
Antiphospholipid
antibody 50, 57, 63, 97, 98, 388
syndrome 387
Antithrombin 5, 38, 61, 63,
64, 92, 139, 140, 144, 159, 163, 266, 270, 271,
355–364, 391
Anti-Xa assay 61, 64, 113, 164,
265–271, 280, 281, 286
Apolipoprotein(a) 393, 407–412
APTT. *See* Activated partial thromboplastin time (APTT)
Assay methods 290–292

B

- Basement membrane 35–36
Batroxobin 143, 274–276
Blood
coagulation inhibitor 80
sampling 115, 193–194, 198
sampling artefacts 59

C

- Centrifuge 49, 57, 58, 64–66, 101, 102,
178, 231, 247, 294, 307–309, 312, 314, 324, 325, 336,
343, 350, 385, 401, 412, 419

Chromogenic

- assays 7, 60, 75, 76, 161,
265, 292, 324, 363, 369, 371
substrate assay 289
test 76
Claus method 184
Clotting
test 111, 121
time 5, 68, 74, 75, 98, 103–107,
111, 117, 119, 126, 127, 135, 136, 184,
186, 188, 189, 191, 273, 275, 276, 283,
285, 286, 292, 330, 337, 341, 344–347,
350, 351, 370, 379, 380
Coagulant inhibitors 5–7
Coagulation
age dependence of coagulation assays 85
assay 9, 49–52, 54, 57, 58, 63, 64, 66, 103, 108, 121, 164,
184, 191, 274, 291, 292
clot-based coagulation tests 74–76
factor 5, 20, 32, 58, 76, 80,
99, 100, 106, 114, 116, 123, 125,
135, 140, 156, 165, 245, 251, 268,
325, 327, 335, 343, 347, 349, 389, 402
monitoring 159
test 9, 56, 62, 74, 81, 85–93,
116, 125, 135, 155, 157, 158, 266, 269, 282, 341,
343, 358, 369, 377
whole blood coagulation time 164

D

- D-dimer 46, 64, 69, 78, 331, 415–426
Deficiency
acquired 114, 124, 172
hereditary 366, 368
Diagnosis 4, 9, 113, 123, 131–133,
172, 187, 200, 207, 208, 214–217, 220, 222,
227, 241, 244, 247–249, 301, 302, 317, 338,
345, 375, 389, 391–393, 397, 398, 403, 415
Dilute Russell's viper venom time
(DRVVT) 64, 103–107, 323,
330, 341–350
Diurnal variation 63
DRVVT. *See* Dilute Russell's viper venom time (DRVVT)
Dysfibrinogenemia 76, 131, 134,
182, 184, 187, 274, 276

E

Endogenous thrombin potential
(ETP)141, 142, 148, 150, 151
Endothelial cells5, 6, 20, 26, 31–39,
161, 171, 289, 365, 374, 393
ETP. *See* Endogenous thrombin potential (ETP)
External quality assurance73, 329

F

Factor VIII16, 59, 63, 64, 76, 102,
113, 114, 181, 245, 321–331,
335, 341, 368, 374
Factor XIII assay171–179
FDP. *See* Fibrinogen/fibrin degradation products (FDP)
Fibrin.....4–6, 8, 9, 37–39,
74, 75, 105, 111, 131, 132, 139, 142, 143, 146, 148,
157, 161, 163, 164, 171–173, 176, 177, 181–184,
194, 244, 253, 273–276, 315, 331, 341, 366, 401,
415–426
Fibrinogen.....5, 8, 15, 16, 18, 20,
23–25, 55, 59, 64, 67, 68, 75, 77, 78, 92, 105, 111,
114, 121–124, 131–133, 139–141, 143, 157, 161,
171, 181–192, 234, 243, 245, 273, 275, 276, 291,
331, 347, 401, 415–426
Fibrinogen/fibrin degradation products (FDP), 132,
415–426
Fibrinolysis.....4, 8, 15, 16, 39, 63,
76, 139, 158, 161, 173, 366,
393, 417, 420
Flow cytometry.....194, 196, 197,
203, 217, 241–254, 315
Fluorescence146, 149, 150, 196,
241, 249, 250, 385
Functional assay.....74, 79, 173, 184,
291–292, 308, 309, 311, 315, 317, 322, 355–356, 362,
366, 368, 369, 374, 377

G

Granules14–18, 25, 34, 37, 208–213,
215–217, 220–222, 245, 249
Guidelines9, 51, 54, 55, 57, 80,
86, 115, 116, 125, 134, 135, 164, 258, 268–270, 282,
377, 390, 391, 399, 403

H

Haematology analyzers.....204, 205
Haemophilia.....80, 82, 83, 119, 128,
153, 179, 180, 240, 331–333
Hemochron157–160
Hemolysis.....51, 56, 60–61, 75, 102,
125, 128, 137, 219, 247, 363, 371, 401
Hemostasis351
Hemotec.....157

Heparin

concentration.....52, 159, 161, 162,
164, 280, 286, 290, 310, 313, 314, 347
monitoring.....57
Heparin-induced thrombocytopenia
(HIT)64, 159, 243,
248, 301–317
Hereditary deficiency.....366, 368
Heterotypic aggregates26, 244–245,
249–251, 253
HIT. *See* Heparin-induced thrombocytopenia (HIT)
Homocysteine.....25, 26, 52, 199, 204,
218, 233, 244–245, 249–251, 253, 312, 418
HPLC383–386
Hypofibrinogenemia.....76, 134, 182

I

Immunoblotting technique.....407–412
Immunological
assay.....73, 78, 303, 356, 366, 374, 376
tests.....77–78
Inhibitor4, 16, 33, 57, 76, 92,
99, 113, 124, 132, 139, 159, 177, 190,
234, 252, 274, 289, 321, 335, 345, 355,
366, 374, 389, 393, 402, 417
INR. *See* International normalized ratio (INR)
Interference50, 60–62, 69, 70, 75, 88, 93,
102, 146, 184, 185, 190, 191, 195, 196, 201–203,
265, 291, 331, 374, 389, 398, 423–424, 426
International normalized ratio (INR).....5, 121–128
Isoelectric focusing407–412

K

Kaolin clotting time (KCT), 103–106, 335–339

L

LA. *See* Lupus anticoagulant (LA)
Laboratory testing104, 105, 157,
227, 315, 388, 397
Light transmission aggregometry227–240
Lipemia50, 61–62, 69, 70,
74, 75, 79, 117, 126, 136, 363, 371, 426
Low molecular weight heparin (LMWH) monitoring.....50,
58, 60, 64, 76, 104, 159, 265, 306, 307
Lupus anticoagulant (LA)57–59, 64, 76,
78, 97–107, 112–114, 124, 132, 133, 330, 331, 335,
341, 349, 351, 368, 374, 388, 390–392, 394, 397,
400, 401

M

MAX-ACT157, 159, 161
Mixing studies99, 101, 103, 106,
114, 124, 347, 351

Monoclonal antibodies..... 78, 100, 189, 194,
241, 245, 246, 251, 252, 293, 294, 310, 314, 330, 379,
394, 396, 419

Morphology..... 194, 207–223

N

Nonparametric..... 90–91, 237

P

Parametric91

Partial thromboplastin time (PTT), 51, 54, 55, 57–59, 62,
64, 65, 67, 68, 189–191

Pathogenesis249

Phenotyping407

Phospholipid 4, 6, 14, 16, 50, 57, 58, 97–104, 106, 107, 112,
117, 122, 126, 140, 145, 149, 150, 157, 158, 330,
335, 337, 341, 342, 346, 347, 349–351, 365, 366,
368, 387–395

Plasma storage.....294

Platelet

activation5, 14, 16–19, 23–26,
33, 37, 50–52, 66, 79, 91, 107, 198, 232, 234, 239,
242–244, 247, 249, 250, 252, 253, 301, 302, 310,
314–317

aggregation15, 18, 20, 22–24, 26,
32, 33, 50, 62, 65, 79, 158, 223, 227,
232–234, 236, 237, 247, 309, 310, 314, 315

count.....57, 79, 102, 107, 186,
193–204, 207, 208, 210, 212, 215–217, 220, 222,
223, 231, 302, 335, 336, 343, 347, 350

disorders 214, 215, 222, 252

free plasma..... 58–59, 65, 67, 116, 125, 135,
174, 269, 282, 336–339, 342, 358, 369, 377

function testing.....230

immunophenotyping242, 246

neutralization.....103, 106, 347, 349–351

physiology.....13–26

receptors17–22

structure.....13–17

Pooled normal plasma 61, 100, 175, 337, 344,
346, 357, 358, 362, 371, 374, 375, 380

Protamine titration 267, 279–286

Protein C 6, 38, 57, 62–64, 68, 78,
92, 139, 140, 365–371, 373, 389, 393

Protein S..... 6, 38, 64, 68, 92, 140,
365, 373–380, 389, 393

Prothrombin Time (PT).....5, 74, 75, 99,
103, 106, 111, 121–128, 131, 157, 184, 292, 323,
368, 374, 377

PTT. *See* Partial thromboplastin time (PTT)

Q

Qualitative99, 132, 173, 273, 291, 292,
308, 399, 417, 418, 421–423

Quality management 80, 81

Quantitative..... 49, 63, 69, 78, 80, 89, 132,
184, 273, 316, 392, 399, 415, 417–419, 422–426

R

Reference

ranges..... 3, 9, 56, 85–93, 113, 114, 118, 119,
123, 124, 128, 133, 137, 187, 193, 237, 239, 271,
337, 344, 345, 362, 367, 375, 376, 420, 422

value..... 86, 90, 93

Reptilase 65, 143, 146, 148, 152, 273–276

S

Sample stability 58, 63, 419

Semi-quantitative 418, 419

Snake venom366

Sodium citrate49–52, 185, 230, 252, 274, 419

Standard curve..... 150, 179, 184, 186–192, 265,
266, 292, 357, 359–362, 371, 374, 375, 380, 424

Standardisation..... 51, 79, 80, 99, 112, 115,
122–123, 125, 132, 134, 266, 268, 280, 309, 390,
394–397, 399, 400, 402, 403, 420–421

T

TFPI. *See* Tissue factor pathway inhibitor (TFPI)

Thrombin

clotting time (TCT), 5, 131–137, 274, 276, 280, 284

generation5–7, 37, 38, 139–153, 161–163,
184, 238, 273, 301, 356, 366, 374

reagent 135, 184, 188

substrate..... 145, 149, 150

time (TT) 65, 132, 133, 157, 285, 331

Thrombocytopenia

heparin-induced64, 159, 243, 248, 301–317

inherited200, 214–216, 219, 223

Thrombocytosis.....193

Thromboembolic risk factors.....407

Thrombophilia100, 363, 368, 376, 400

Tissue factor pathway inhibitor
(TFPI)6, 7, 289–298, 393

Turbidimetric aggregation assays.....227

V

Vacuainers401

Vascular tone 31–35, 40

Vessel wall..... 4, 7, 31–40, 289